Literature DB >> 26032104

Therapy: Metformin takes a new route to clinical efficacy.

Marc Foretz1, Benoit Viollet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26032104      PMCID： PMC4676264          DOI： 10.1038/nrendo.2015.85

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Authors:  A Maida; B J Lamont; X Cao; D J Drucker
Journal:  Diabetologia       Date:  2010-10-23       Impact factor: 10.122

2.  Metformin and the intestine.

Authors:  C J Bailey; C Wilcock; J H B Scarpello
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

3.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

4.  Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.

Authors:  Clémence D Côté; Brittany A Rasmussen; Frank A Duca; Melika Zadeh-Tahmasebi; Joseph A Baur; Mira Daljeet; Danna M Breen; Beatrice M Filippi; Tony K T Lam
Journal:  Nat Med       Date:  2015-04-06       Impact factor: 53.440

5.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

Review 6.  Metformin: from mechanisms of action to therapies.

Authors:  Marc Foretz; Bruno Guigas; Luc Bertrand; Michael Pollak; Benoit Viollet
Journal:  Cell Metab       Date:  2014-10-30       Impact factor: 27.287

7.  Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.

Authors:  Frank A Duca; Clémence D Côté; Brittany A Rasmussen; Melika Zadeh-Tahmasebi; Guy A Rutter; Beatrice M Filippi; Tony K T Lam
Journal:  Nat Med       Date:  2015-04-06       Impact factor: 53.440

8.  Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Authors:  Russell A Miller; Qingwei Chu; Jianxin Xie; Marc Foretz; Benoit Viollet; Morris J Birnbaum
Journal:  Nature       Date:  2013-01-06       Impact factor: 49.962

9.  Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

Authors:  Antonella Napolitano; Sam Miller; Andrew W Nicholls; David Baker; Stephanie Van Horn; Elizabeth Thomas; Deepak Rajpal; Aaron Spivak; James R Brown; Derek J Nunez
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

10.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.

Authors:  Anila K Madiraju; Derek M Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T Braddock; Ronald A Albright; Brett J Prigaro; John L Wood; Sanjay Bhanot; Michael J MacDonald; Michael J Jurczak; Joao-Paulo Camporez; Hui-Young Lee; Gary W Cline; Varman T Samuel; Richard G Kibbey; Gerald I Shulman
Journal:  Nature       Date:  2014-05-21       Impact factor: 49.962
  10 in total
  5 in total

1.  Small extracellular vesicle-mediated targeting of hypothalamic AMPKα1 corrects obesity through BAT activation.

Authors:  Edward Milbank; Nathalia R V Dragano; Ismael González-García; Marcos Rios Garcia; Verónica Rivas-Limeres; Liliana Perdomo; Grégory Hilairet; Francisco Ruiz-Pino; Patricia Mallegol; Donald A Morgan; Ramón Iglesias-Rey; Cristina Contreras; Luisa Vergori; Juan Cuñarro; Begoña Porteiro; Aleix Gavaldà-Navarro; Rebecca Oelkrug; Anxo Vidal; Juan Roa; Tomás Sobrino; Francesc Villarroya; Carlos Diéguez; Rubén Nogueiras; Cristina García-Cáceres; Manuel Tena-Sempere; Jens Mittag; M Carmen Martínez; Kamal Rahmouni; Ramaroson Andriantsitohaina; Miguel López
Journal:  Nat Metab       Date:  2021-10-21

2.  Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study.

Authors:  Marta Riera-Borrull; Anabel García-Heredia; Salvador Fernández-Arroyo; Anna Hernández-Aguilera; Noemí Cabré; Elisabet Cuyàs; Fedra Luciano-Mateo; Jordi Camps; Javier A Menendez; Jorge Joven
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

3.  Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice.

Authors:  Eliska Vacurova; Jaroslava Trnovska; Petr Svoboda; Vojtech Skop; Vendula Novosadova; David Pajuelo Reguera; Silvia Petrezselyová; Benoit Piavaux; Berwini Endaya; Frantisek Spoutil; Dagmar Zudova; Jan Stursa; Magdalena Melcova; Zuzana Bielcikova; Lukas Werner; Jan Prochazka; Radislav Sedlacek; Martina Huttl; Sona Stemberkova Hubackova; Martin Haluzik; Jiri Neuzil
Journal:  Nat Commun       Date:  2022-04-06       Impact factor: 17.694

4.  Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.

Authors:  Su-Jin Rhee; YoonJung Choi; SeungHwan Lee; Jaeseong Oh; Sung-Jin Kim; Seo Hyun Yoon; Joo-Youn Cho; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2016-08-10       Impact factor: 4.162

5.  Fernblock® Upregulates NRF2 Antioxidant Pathway and Protects Keratinocytes from PM2.5-Induced Xenotoxic Stress.

Authors:  Pablo Delgado-Wicke; Azahara Rodríguez-Luna; Yoshifumi Ikeyama; Yoichi Honma; Toshiaki Kume; María Gutierrez; Silvia Lorrio; Ángeles Juarranz; Salvador González
Journal:  Oxid Med Cell Longev       Date:  2020-04-14       Impact factor: 6.543
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.